Sudip Bandopadhyay, Market Expert told CNBC-TV18, "Pharma has become a high beta space. The risk and reward are both high. So one has to take the pharma space not as a sector but company specific."
"We still believe that Lupin continues to be the best bet. It has got all the right ingredients, they have got all the FDA blessings and are in a much better position to move up significantly from the current level," he said.